Germline mutations of BRCA1 and BRCA2 confer a particularly high life‐time risk of developing breast (BC) and ovarian (OC) cancer.1, 2 Following an autosomal dominant pattern of inheritance, they are passed on to subsequent generations with a probability of 50% and consequently result in familial aggregation of disease. The gene discussed is BRCA2; the disease is breast cancer.